IMMUNE Pharmaceuticals COMPANY PROFILE: have broad applications across a range of disease states, and Immune is exploring opportunities in nonalcoholic steatohepatitis (NASH) and severe asthma as well. The Company is developing AmiKet, a phase III ready topical drug for the treatment of Neuropathic Pain and is seeking a development and commercial partner. Immune is also developing NanomAb®, antibody nanoparticle conjugates for the targeted delivery of chemotherapeutics. Immune has strategic partnerships with Yissum Research Development Company of the Hebrew University of Jerusalem and STC Immune Pharmaceuticals, Inc. (NASDAQ: IMNP), headquartered in New York City, applies a personalized, bio-marker based approach to treating inflammatory diseases and cancer through the development of novel, targeted, monoclonal antibody therapeutics. Immune’s lead clinical candidate bertilimumab targets eotaxin-1, a mediator of inflammation. The candidate is in Phase II trials for ulcerative colitis (UC) and bullous pemphigoid (BP), with initial human data expected in late 2015 for BP and the second half of 2016 for UC. Bertilimumab may biologics, a Cambridge-based biotech company. 2015 Milestones / Catalysts Resume patient enrollment process for phase II in BP and UC with Bertilimumab Orphan Drug designation for Bertilimumab in BP Pre-clinical Data availability for Bertilimumab in NASH Initial Results of Bertilimumab Bullous Pemphigoid (BP) phase II study Initiation of Bertilimumab NASH clinical development program Q2 2015 Q3 2015 Q3 2015 Q4 2015 Q4 2015 Quarter 2 Quarter 3 Quarter 4 Partnering of AMIKET US IND filing for Bertilimumab in BP Initiation of Amiket NP development NanomAb Partnerships Initiation of Amiket PHN phase III Q2 2015 Q2 2015 Q3 2015 Q3/Q4 2015 Q4 2015 SENIOR MANAGEMENT TEAM: ANALYST COVERAGE: Dr. Daniel Teper, Chief Executive Officer Paul Nadler, MD, Chief Medical Officer Gad Berdugo, Chief Financial Officer Gbola Amusa, MD—Chardan Capital Markets Vernon T. Bemardino—MLV & Co. Jerry Isaacson, PhD—LifeSci Advisors Jason Napodano—Zacks Investment Research, Inc. BOARD OF DIRECTORS: Daniel Kazado, Chairman Cameron Durrant, MD, Lead Independent Director and Chair of the Compensation Committee Elliot Maza, Chair of the Audit Committee Rene-Pierre Azria, Chair of the Transaction Committee Dr. Daniel Teper, Chief Executive Officer CONTACT: Anna Baran Senior Director, Corporate Affairs IMMUNE Pharmaceuticals Inc. 430 East 29th Street, Suite 940, New York, NY 10016 Phone: 646-440-9311 [email protected] High Levels of Eotaxin-1 Are Expressed In Patients With Inflammatory Diseases in Multiple Organs Liver diseases and Gastro-Enterology Respiratory Severe Asthma Non Alcoholic SteatoHepatitis (NASH) Primary Sclerosing Cholangitis (PSC) Ulcerative Colitis Crohn’s Disease Dermatology Bullous Pemphigoid Eotaxin-1/ CCL11 Bullous Pemphigoid (BP) BP is a rare autoimmune blistering cured, it can be managed. The addressable global market for skin disease that typically affects individuals older than 65 years. biologics in severe asthma is expected to reach $7.5 billion in sales. Currently, there is no cure for BP. The US/EU market size is Nonalcoholic steatohepatitis (NASH) NASH is liver inflammation currently estimated at 60,000 patients. The addressable global market for Bertilimumab in BP could reach $1.6 billion. and damage caused by a buildup of fat in the liver. NASH is the most severe form of non-alcoholic fatty liver disease (NAFLD) IBD (Crohn’s and Colitis) Crohn’s disease and ulcerative colitis and is regarded as a major cause of cirrhosis of the liver of are debilitating chronic inflammatory diseases of the digestive unknown cause. The market for NASH drugs is expected to grow tract. The estimated market for biologics in moderate-to-severe to over $10 billion IBD patients is estimated to grow to $10 billion. Companion Diagnostic Eotaxin-1/ CCL11 is a biomarker Severe asthma Asthma is a chronic, inflammatory lung disease that of multiple inflammatory diseases. Immune plans to develop a narrows the airways. Severe asthma attacks may require emergency companion diagnostic which may support patient selection care and can be fatal. While asthma is a disease that cannot be for personalized and targeted treatment. Clinical Stage Portfolio With Multiple Shots on Goal Resources Prioritized For Bertilimumab Phase II BP And UC Trials
© Copyright 2024